Arrowhead Research ARWR Business Segments — Candidate costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept arwr:ResearchAndDevelopmentExpenseCandidateCosts.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's business segments — candidate costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's business segments — candidate costs?
- Arrowhead Research (ARWR) reported business segments — candidate costs of $99.45M in Q1 2026.
- How has Arrowhead Research's business segments — candidate costs changed year-over-year?
- Arrowhead Research's business segments — candidate costs increased by 39.7% year-over-year, from $71.19M to $99.45M.
- What does business segments — candidate costs mean?
- Direct costs incurred for the development and clinical testing of specific drug candidates.
- How do you interpret business segments — candidate costs?
- An increase suggests accelerated clinical trial activity or advancement of candidates into later-stage development, while a decrease may indicate project completion or pipeline prioritization.
- How does business segments — candidate costs compare across companies?
- Commonly reported by biotechnology firms as 'Clinical Trial Expenses' or 'Direct Pipeline Development Costs'.